Drug Profile
NSA 789
Alternative Names: NSA-789Latest Information Update: 02 Sep 2021
Price :
$50
*
At a glance
- Originator Wyeth
- Developer Pfizer
- Class Antidementias; Antipsychotics; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Alzheimer's disease; Schizophrenia
Most Recent Events
- 02 Sep 2021 Discontinued - Phase-I for Alzheimer's disease in USA (PO)
- 02 Sep 2021 Discontinued - Phase-I for Schizophrenia in USA (PO)
- 20 Aug 2021 Wyeth withdraws a phase I trial in Schizophrenia in USA (PO)(NCT00892021)